Current state and clinical outcome in Turkish patients with hepatocellular carcinoma

doi:10.4254/wjh.v10.i1.51

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5827)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

413

WORD

291

HTML

2968

Figures (1-2)

185

Tables (1-5)

195

Sum=4052

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

954

Download

821

Sum=1775

Jan 27, 2018 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jan 27, 2018; 10(1): 51-61
Published online Jan 27, 2018. doi: 10.4254/wjh.v10.i1.51

Table 2 Baseline demographic, clinical and laboratory characteristics of patients

Characteristics
Number of patients (%)	545 (100)
Male, n (%)	449 (82)
Female, n (%)	96 (18)
Age (yr)
Mean ± SD	59.5 ± 10
Median (range)	60 (19-85)
Chronic liver disease, n (%)	532 (97.6)
Chronic viral hepatitis, n (%)	454 (83.3)
HBV (monoinfection)	287 (52.6)
HCV (monoinfection)	120 (22)
Hepatitis D	37 (6.7)
HBV + HCV co-infection	10 (1.8)
Cirrhosis, n (%)	477 (87.5)
Child A	247 (45.3)
Child B	140 (25.7)
Child C	90 (16.5)
Diagnostic method for HCC, n (%)
CT	26 (4.8)
MRI	433 (79.4)
Liver biopsy	86 (15.8)
Treatment, n (%)
No treatment	238 (43.7)
Hepatic resection	27 (5)
OLT	56 (10.3)
TACE	172 (31.5)
Yttrium-90 radioembolization	19 (3.5)
RFA	12 (2.2)
Ethanol/acetic acid ablation	5 (0.9)
Sorafenib	16 (2.9)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; CT: Computerized tomography; MRI: Magnetic resonance imaging; OLT: Orthotopic liver transplantation; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation.

Citation: Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, Poyanli A, Gulluoglu M, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol 2018; 10(1): 51-61
URL: https://www.wjgnet.com/1948-5182/full/v10/i1/51.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i1.51